Aurora Cannabis Reports Strong Q3 Medical Cannabis Growth, Strategic Divestment, and Announces $100M ATM Program
ACB sits 18% above its 52-week low of $3.422.
Summary
Aurora Cannabis announced strong Q3 results driven by record medical cannabis sales, alongside a strategic pivot away from low-margin consumer markets and the initiation of a substantial $100 million ATM equity program for future growth initiatives.
Key Events · Financing and Capital Events · ACB
-
Strong Q3 Financial Performance
Reported record global medical cannabis net revenue of $76.2 million (up 12% YoY), $18.5 million in Adjusted EBITDA, and $15.5 million in free cash flow for fiscal Q3 2026.
-
Strategic Business Restructuring
Exiting lower-margin Canadian consumer cannabis markets and divesting its controlling interest in Bevo Agtech to focus on the higher-margin global medical cannabis business.
-
New $100 Million ATM Program
Established an At-The-Market (ATM) equity program to issue up to U.S. $100 million in common shares, intended for strategic and accretive purposes including cultivation capacity and M&A.
-
Positive Full-Year 2026 Outlook
Provided guidance for annual global medical cannabis net revenue between $269M and $281M, and consolidated adjusted EBITDA between $52M and $57M.
Analysis · ACB · Life Sciences
Aurora Cannabis reported robust fiscal Q3 2026 results, highlighted by a record $76.2 million in global medical cannabis net revenue, representing a 12% year-over-year increase. The company also achieved $18.5 million in Adjusted EBITDA and generated $15.5 million in free cash flow, demonstrating improved operational efficiency. Strategically, Aurora is exiting certain lower-margin Canadian consumer cannabis markets and divesting its controlling interest in Bevo Agtech, aiming to focus resources on its higher-margin global medical cannabis business. Concurrently, the company announced a new At-The-Market (ATM) equity program to issue up to U.S. $100 million in common shares. While this ATM represents a substantial potential capital raise and dilution, the company states the proceeds will be used for strategic and accretive purposes, including increased cultivation capacity and potential M&A. The filing also provides positive full-year 2026 guidance, projecting increased medical cannabis revenue and adjusted EBITDA.
At the time of this filing, ACB was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.2M. The 52-week trading range was $3.42 to $6.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.